293780 — AptaBio Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩193bn
- KR₩190bn
- KR₩324m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS/A |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 46,158 | 42,825 | 22,911 | 16,995 | 51,885 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 323 | 680 | 479 | 3,047 | 2,659 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 46,767 | 43,745 | 23,777 | 20,419 | 57,474 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 4,033 | 4,889 | 4,822 | 5,848 | 5,129 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 77,404 | 75,444 | 64,911 | 56,114 | 92,519 |
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 731 | 801 | 788 | 1,040 | 818 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 2,249 | 3,403 | 3,246 | 3,744 | 31,156 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 75,155 | 72,040 | 61,665 | 52,370 | 61,363 |
Total Liabilities & Shareholders' Equity | 77,404 | 75,444 | 64,911 | 56,114 | 92,519 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |